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Abstract 
Gene silencing using RNA-interference, first described in mammalian systems almost a decade ago, is 
revolutionizing therapeutic target validation efforts both in vitro and in vivo. Moreover, the potential for 
using short interfering RNA (siRNA) as a therapy in its own right is also progressing at a significant 
pace. However, the widespread use of such approaches is contingent on having appropriate delivery 
systems to achieve clinically appropriate, safe, and efficient delivery of siRNA. There are many 
physicochemical and biological barriers to such delivery, and a growing emphasis on the design and 
characterisation of non-viral technologies that will overcome these barriers and expedite targeted 
delivery. This review discusses the considerations and challenges associated with use of siRNA-based 
therapeutics, including stability and off-target effects. Speculation is made on the properties of an ideal 
delivery system and the non-viral delivery approaches used to date, both in vitro and in vivo, are 
classified and discussed. Moreover, the ability of cyclodextrin-based delivery vectors to fulfil many of 
the criteria of an ideal delivery construct is also elaborated. 
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Introduction:  
“Silence is the perfectest herald of joy” 
William Shakespeare (1564 - 1616), "Much Ado about Nothing", Act 2 scene 1 
The promise of gene therapy-based medicine is slowly being realised and heralding much joy to patients 
suffering from a host of hitherto incurable disorders. The goal of gene therapy, is to either silence 
aberrant disease causing genes, amplify the functions of other genes or interfere with the expression of 
infectious agents or malignant cells
[1]
. Among those most widely used have been the introduction of 
plasmid DNA and the use of antisense technology. The discovery of gene silencing by RNA interference 
(RNAi) has revolutionarised this area and presents new opportunities for the successful achievement of 
gene-based therapies. Moreover, modern biomedical research heavily depends on genomic and 
proteomic strategies that help uncover disease mechanisms and detect potential target genes relevant to 
the disease pathology
[2]
. Therapeutic targets identified from the use of such high-throughput 
technologies warrant comprehensive in vivo validation of their aetiological role in the disease
[3]
. Gene 
silencing by RNAi thus offers itself as very suitable ways to identify how a system functions with the 
given gene abrogated. However, the future success of RNAi-based approaches is dependent on the 
design of efficient and effective delivery technologies. Design of delivery systems has been greatly 
informed by earlier experiences with delivery of other nucleic acids such as plasmid DNA (pDNA), 
oligonucleotids, ribozymes and DNAyzmes. Although there are some intrinsic differences between 
delivering each of these candidates, they also share many common characteristics. This review highlights 
the synthetic material-based delivery approaches in the rapidly developing area of short interfering 
(siRNA) therapy and details the barriers to, and the methods currently used to deliver siRNA both in 
vitro and in vivo.  
 
The RNAi pathway and siRNA 
RNAi is a process in which double-stranded RNA (dsRNA) inhibits gene expression in a sequence 
dependant manner through degradation of the corresponding mRNA. Fire et al. 1998
[4]
 described the use 
and potency of dsRNA, first seen and investigated in plants
[5]
 , to elicit changes in gene expression in the 
nematode Caenorhabditis elegans.  This work led to Andrew Fire and Craig Mello being awarded the 
Nobel Prize in 2006. The first demonstration in 2001 that siRNA duplexes could be used in mammalian 
cells to suppress gene expression
[6]
, provided a new tool for studying gene function in mammalian cells 
and that may eventually be developed into gene-specific therapeutics. Since these initial reports of RNAi 
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have emerged, it is hoped that this system can be exploited to develop a new class of drugs and numerous 
review articles have been published focusing on the evolution of RNAi as a therapeutic strategy
[7-9]
. 
RNAi is a mechanism that has been evolutionarily conserved among species (protozoa, fungi, plants and 
animals) and plays an innate immune security role in defending harmful effects of invasive nucleic acids 
from viruses, transposable elements and other pathogens, i.e. bacteria
[10, 11]
. RNAi pathways are 
maintained by small RNAs that mainly include microRNA (miRNA) and siRNA (see Figure 1 a pictorial 
representation of the major compants of the RNAi pathway). miRNA induces translational suppression 
and transcript deprivation for imperfectly complementary messenger RNA (mRNA), whereas siRNA 
mediates gene knockdown via sequence-specific cleavage of perfectly matching targets 
[7]
. 
======================================================= 
Insert Figure 1 about here 
====================================================== 
 
It is possible to utilize the RNAi mechanism for siRNA in three ways, including: A) the introduction of a 
plasmid or viral-based vectors to the nucleus in order to express shRNA; B) the introduction of shRNA 
into the cytoplasm to allow dicer processing and subsequently get loaded into the RISC; C) the 
introduction of synthetic siRNA into the cytoplasm to directly allow RISC loading (see Figure 1).  
Viral-based vector approaches have largely dominated clinical trials in gene therapy to date due to their 
relatively high transfection efficiency
[12]
. However, such gene carriers have many potential side effects, 
such as immunotoxicity and mutagenesis
[12]
. The recent case, in which a retroviral vector’s site of 
insertion into the genome appears to have activated a cancer-causing gene, has come further endorsed 
the search for efficient non-viral delivery technologies
[12]
.  
While the molecular understanding of the RNAi pathway is progressing, and new therapeutic targets for 
the treatment of a wide range of diseases are continuously identified, none of these therapies can be put 
into practice until efficient delivery of siRNA is achieved.   
 
Challenges and considerations associated with the use of siRNA 
Naturally occurring small RNAs exist in a relatively perfect equilibrium with their precursors and 
targets, undertaking evolutionary conserved cellular functions
[13]
. A variety of harmful/unexpected 
consequences may result from the non-optimized siRNA candidates, as this may disturb the existing 
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balance in the endogenous small RNA processed pathways within the cells
[13, 14]
.  Therefore, there are a 
number of considerations that must be taken into account in overcoming the challenges for siRNA 
knockdown including minimising off-target effects including immunogenicity, and increasing the 
stability of synthetic siRNAs in the physiological milieu.  
Avoiding Off-target Effects  
The goal of siRNA-based gene therapy strategies is that it silences only the gene of interest. However, a 
number of important factors need to be taken into account when selecting siRNAs to ensure that 
specificity is achieved. There are two major classes of off-target effects described for siRNA 
including
[13, 14]
, these being, i) non-specific silencing resulting from binding of siRNA to sequences other 
than the specific target sequence, and ii) initiation or enhancement of the innate immune response by 
some motifs or patterns in the siRNA. Efforts to overcome such non-specifity are driven at many levels. 
Based on the secondary structures of siRNAs/targets and the nucleotide sequences of siRNAs/targets, 
many computational methods have been developed to seek siRNA sequences that are able to silence the 
expression of their complementary genes
[15-18]
. BLAST (Basic Local Alignment Search Tool) is one of 
the most commonly used bioinformatics programmes and provides identifications of target sequences. 
Genome-wide expression analysis, i.e., by microarray technology, can afterwards be used to confirm, 
validate and further refine the algorithms
[19]
. However, it has been reported that siRNA with as few as 11 
nucleotides homology can lead to off-target knockdown
[20]
. Birmingham et al.
[21]
 reported that off-target 
effects mostly occur due to 3’-UTR seed matches, but not overall homology between siRNA and its 
target. Moreover, it has been reported that siRNA-induced toxicity can be promoted by a preponderance 
of specific motifs such as –UGGC- and other –AU- rich pentamers including -AUUUG, GUUUU, 
AUUUU, CUUUU, UUUUU, GUUUG-
[22]
 thus use of such motifs should be minimized if possible. 
One way to reduce off-target effects is by means of nullifying the formation of siRNA-sense-RISC and 
enhancing the incorporation of siRNA-antisense-RISC
[23, 24]
. As the 5’-phosphate group is essential for 
the siRNA strand to act as a guide strand, modification of the 5’-phosphate group of the sense strand to a 
5’-O-methyl, e.g., can effectively avoid sense-RISC incorporation[23]. Moreover, position-specific and 
sequence-independent chemical modifications such as 2’-O-methyl ribosyl substitution in the seed 
region (2-8 nucleotides within the 5’ end of the guide strand) of antisense strands of the siRNA can also 
reduce off-target effects
[24]
. 
The innate immune response can be triggered as siRNA is also exposed to endosomal and cytoplasmic 
RNA-sensing receptors of the immune system while being transfected into cells. An initial study 
demonstrated that dsRNA (double stranded RNA) with longer than 30 bases can induce recognition of 
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serine/threonine protein kinase receptor (PKR-a cytosolic RNA-binding receptor)
[25]
. Activation of PKR 
is considered to be responsible for virus- and dsRNA-induced production of type I interferons (IFNs) 
found in most mammalian cell types. In some instances, siRNAs can also trigger this pathway
[26]
, 
potentially leading to non-specific effects and toxicity from the ensuing inflammatory response.  
Moreover, as siRNA can possess the same molecular signatures as viral RNA, i.e., unmethylated 
deoxycytidyl-phosphate-deoxyguanosine (CpG) dinucleotides, which are prone to induce an immune 
response via toll-like receptor (TLR) activation. TLRs are a family of receptors which act on the cell 
surface to detect pathogen-specific molecules
 [9, 13, 14]
.  siRNA
[27, 28]
 can activate TLR 3 and TLR 7/8 
[29, 
30] 
and produce pro-inflammatory cytokines upon stimulation. TLR 7/8 activation, in some cases, is 
sequence-dependent as immuno-stimulatory siRNA sequence motifs, such as 5’-UGUGU-3’[31] or a 9-nt 
bases 5’-GUCCUUCAA-3’ have been identified which activate this receptor[30]. In addition, the immune 
response can be also induced by many other sequences, which do not contain any GU bases and dsRNAs 
with high uridine motifs
[32]
. 
Certain approaches have been suggested to alleviate the undesired off-target effects and decrease the 
immune responses. These include
[13, 14]
:  
a) avoiding the use of immuno-stimulatory sequence motifs and high uridine content  
b) nullification of the immune response by introducing modifications (like 2’-deoxy, 2’-O-
methyl, 2’-fluoro and etc.) in the nucleotides and/or their backbone while maintaining 
silencing activity
[32, 33]
  
c) ensuring that siRNA has a 2-nt 3’ overhang, as siRNAs without such overhangs activate the 
interferon system 
[34]
.  
Moreover, synthetic siRNAs have recently reported to saturate some components of the cellular RNAi 
pathway, resulting in a limited capacity to assemble the RISC complex on exogenous siRNAs
[14, 35]
. It is 
suggested that considering of the dose of siRNA is employed, which should be as low as possible to 
preclude saturation of some factors in the RNAi pathway, like Exportin-5, leading to dysregulation of 
critical mechanisms involved in the endogenous RNAi pathway
[14, 35]
. 
 
Increasing stability of siRNA via chemical modifications 
One of the main issues that must be addressed before the therapeutic promise of siRNA therapy can be 
completely fulfilled is the stability of the siRNA in the appropriate bodily fluid, with plasma/serum 
being the most widely studied given the propensity for degradation of the siRNA by serum nucleases
[9]
. 
Increasing efforts have been focused on enhancing siRNA stability by a variety of chemical 
modifications whilst not compromising silencing ability per se. Certain chemical modifications can be 
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introduced almost all bases of both RNA strands, whereas other specific modifications must be placed 
only at certain positions within the siRNA strands
[36]
. For example, stability against nuclease degradation 
can be achieved via the introduction of a phosphorothioate (P=S) backbone linkage at the 3’ end for 
exonuclease resistance and a 2’ modifications (2’-O-methyl and 2’-fluoro) for endonuclease resistance[37-
40]
. In relation to maintaining RNAi silencing activity, exonuclease-stabilizing modifications are well 
tolerated. Many studies have indicated that the introduction of P=S linkages into siRNA does not alter 
the silencing activity of siRNAs
[37, 41, 42]
. Although substitution of P=S oligonucleotides is the most 
common stabilizing modification for both antisense and siRNA, P=S oligonucleotides tend to bind 
nonspecifically to proteins, thus increasing the risk of toxicity
[43]
. However, most current siRNA designs 
now only include a few P=S linkages thus minimising the risk of protein binding. Moreover, it has been 
demonstrated that boron phosphorus (BO) linkages could similarly enhance gene silencing activity at 
lower concentrations and improve resistance to degradation by nucleases compared with unmodified 
siRNA
[44]
. 
Other modifications that have received a lot of attention are the 2’-O-methyl (Me), 2’-O-methoxyethyl 
(MOE) and 2’-fluoro (F) modifications  which demonstrate high specificity in addition to protecting 
against nuclease degradation
[23, 37]
. Introduction of internal sugar modifications that are resistant to 
endonucleases is also generally well tolerated but is dependent on the position of the modification within 
the duplex: the sense strand being more apt to modification compared with the antisense one. The 
incorporation of 2’-O-Me and 2’-O-MOE in the sense strand of siRNA does not appear to have a 
significant effect on activity
[45]. The siRNAs with modified residues at the 5’ end of the antisense strand 
seem to be less active than those modified at the 3’ end. The 2’-F residue is commonly well tolerated on 
the antisense strand, whereas the 2’-O-MOE modification leads to loss of activity irrespective of the 
location in the construct. 
Other highly enhanced oligonucleotide chemistries have also been developed, such as 2’-OH 
modifications, peptide nucleic acids (PNAs), morpholino compounds, locked nucleic acids (LNAs) and 
hexitol nucleic acids (HNAs)
[46, 47]
. Of these LNAs, a family of conformationally locked nucleotide 
analogues, have by far the most promise as they are bestowed with very high affinity nuclease resistance 
to DNA and RNA oligonucleotides
[166]
. Studies in the antisense field over the past decade have shown 
that LNAs combine substantially increased potency in vitro and in vivo with minimal toxicity over other 
chemistries
[167]
. PNAs on the other hand are neutrally charged molecules, solubility and cellular uptake 
are serious problems that have to be addressed for the widespread application of PNAs as antisense 
agents
[46]
. Moreover, the target affinity of morpholino compounds is generally lower than the strength of 
RNA binding achieved with many of the other modifications
[46]
. With recent progresses in nucleotide 
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chemistry, these modifications described in this section may stabilise the siRNA duplex against nuclease 
degradation and last longer than naked siRNAs when they are formulated into various carrier systems for 
in vivo delivery
[48]
. 
 
Challenges and considerations associated with the delivery of siRNA 
Once siRNA has been refined and synthesised to have a high specificity of action and be non-
immunogenic, the next major and perhaps the most important obstacle to its use as a therapeutic agent, or 
in therapeutic target validation research efforts, is how to achieve efficient and specific delivery of the 
siRNA. While much research has gone into the development of viral vectors for use as delivery carriers 
for siRNA therapies, as alluded to earlier there are a number of safety issues associated with their use in 
humans
[12]
. The immune response to viral-based vectors limits their application in repeated 
administration schedules. Moreover, the potential for mutagenesis may also cause unexpected 
consequences to the host
[12]
. Clinical trials involving non-viral-vector based gene therapies have 
dramatically increased from 2004 to 2007, while the number of viral vector trials is steadily dropping 
over the same period
[49, 50]
. Thus, we will focus our attention for the remaining part of this review on the 
significant advances and improvements in non-viral delivery technologies and how they can be applied 
to siRNA-based therapeutics. 
When designing a drug delivery system for siRNA one of the first considerations to be taken is whether 
to develop a delivery formulation for systemic or local administration. Local delivery offers several 
advantages over systemic, including lower doses, ease of access, less potential side-effects and 
facilitation of site-specific delivery. Alternatively, systemic delivery via intravenous (i.v.) or oral 
administration is more applicable where the disease site is not easily accessible. Before the delivery can 
successfully occur however the barriers encountered by siRNA in the extracellular and intracellular 
environments must be addressed. 
Extracellular barriers to siRNA delivery 
Gene packaging. The negative charge (nearly 40 anionic charges) and size (two turns of a nucleic acid 
double helix) of siRNA suggests that it is unlikely to bind or cross the cell membrane unaided
[51]
. Much 
of our knowledge regarding gene packaging to facilitate siRNA delivery has come from decades of 
research focused on studying DNA delivery aided by cationic non-viral vectors. Cationic materials can 
also bind to and condense siRNA into small, compact structures through electrostatic interactions 
between positive charges exposed on the vector material and the negative phosphates on the RNA 
backbone, thus spontaneously forming polyplexes
[48]
. The resulting particles are capable of protecting 
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siRNA from nucleolytic enzymes by steric blocking, thereby prolonging the half-life of siRNA 
substantially. In addition, complete siRNA encapsulation is also capable of avoiding the recognition of 
TLR 3
[27]
 which as stated earlier is an important facilitator of off-target immune activation. 
Serum stability. Research on cationic polyplexes has illuminated the potential drawbacks that hinder 
their successful in vivo application
[48]
. The major stability problems encountered with siRNA complexes 
are aggregation and decomposition. The serum stability of the siRNA-vector constructs depends on the 
polymeric structure, as well as on the overall zeta potential (surface charge of polyplexes in colloidal 
systems). As unmodified neutral polyplexes quickly form large aggregates in physiological salt 
environments, they are generally ineffective gene-delivery agents and can even be toxic in vivo due to 
embolization of the aggregations in the lung
[48, 52]
. It is of important to note that as positively charged 
polyplexes can adsorb serum albumin and other anionic proteins, aggregation of clot-like accumulations 
in the blood can occur
[53]
. These large masses subsequently are either entrapped in the lung endothelial 
capillary bed or taken up by reticuloendothelial system (RES)[54].  
One of the best characterised methods to overcome uptake by RES is the addition of polyethylene-glycol 
(PEG).  The process of PEGylation was first described in the 1970s
[55, 56]
.  This polymer is highly soluble 
in aqueous solution and is approved for use by the Food and Drug Administration (FDA) as a result of its 
non-toxic, non-immunogenic and non-antigenic properties
[57]
. It has since been used extensively, to 
improve the pharmacokinetic and pharmacodynamic properties of drugs including biologicals, and as a 
component in gene delivery constructs
[57-60]
. PEGylation is generally used to increase the water solubility 
of molecules, prolong their systemic circulation, limit toxicity
 
in addition to avoiding uptake by the 
RES
[57-60]
. siRNA-based carrier systems can escape from RES when they have a diameter less than 
100nm and a neutral surface charge or if the particle surface is protected by polymers PEG
[54]
. When 
grafted onto the polymer as a ‘brush’, PEG can shield positively charged surfaces, thus stabilizing 
polyplexes against salt-, protein- and complement-induced inactivation
[48, 54]
. The charge shielding and 
steric effects provided by PEGylation result in reduced particle-particle and particle-protein interactions. 
There are, however, a few limitations in the use of PEG including polydispersity inside the body and 
excretion from the body
[57]
. Interestingly it has been shown that whilst PEGylation conferred salt 
stability to particles it also produced a reduction in gene expression
[61]
, possibly resulting from 
significant affects of PEGylation on cellular uptake and intracellular trafficking of non-viral gene 
delivery particles. Moreover, it should be noted that there is accumulating evidence suggesting that the 
PEGylated component of liposomes (vesicles with a water compartment entrapped in a phospholipid 
bilayer), maybe immunogenic in its own right and promote antibody, especially IgM, responses against a 
second dose of such liposomes. This suggests that any PEGylated liposomal formulation may display 
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unexpected pharmacokinetic behavior upon repeated injection and, as a consequence, may show less 
therapeutic efficacy or even cause undesirable side effects
[62]
. 
Cell-specific targeting. Polypolexes normally do not have the capacity for cell-specific targeting, 
especially after PEGylation, due to the shielding of the cationic surfaces. However, PEG allows for 
flexible chemistry to enable the attachment of targeting moieties that allow both cell specificity and 
increased cell uptake
[48, 58]
. The detection of receptors overexpressed in certain tissues or disease states 
lends itself to the design of a targeted delivery system. Conjugating targeting proteins such as antibodies, 
which have high specificity for their corresponding antigens, to the delivery vector has been shown to be 
an effective method to increase cellular uptake of siRNA both in vitro and in vivo
[63-65]
. Oh and 
colleagues
[66]
 have shown that the aminopeptidase P antibody specifically targeted nanoparticles to the 
caveolae of rat lung endothelium, thus providing a novel targeting delivery system for siRNA. On the 
other hand, Kumar et al.
[67]
 reported the T cell specific delivery of anti-HIV siRNA in a mouse model. 
Treatment with siRNA conjugated to a peptide and an anti-CD7 antibody ensured selected delivery of 
the siRNA and led to suppression of the virus and prevention of the loss of CD4 T cells
[67]
.  
Integrins, adhesion molecules that bind to components of the extracellular matrix and act as 
sensor/signalling molecules, can also be used as targeting moieties
[68-70]
. In particular, the integrin 
lymphocyte function-associated antigen-1 (LFA-1) expressed on all leukocytes, which mediates 
heterotypic adhesion to intercellular adhesion molecules on other immune cells, undergoes remarkable 
conformational changes in response to stimulation
[68]
. Peer et al.
[68] 
utilised this approach to target 
siRNAs to primary leukocytes, more specifically those expressing the high affinity adhesive form of 
LFA-1 as opposed to the low affinity non-adhesive LFA-1 found on naive cells and thus interrupting 
unwanted pathogenic immune stimulation. Intravenously injected siRNA complexes have been shown to 
selectively target K562 cells expressing the high affinity LFA-1 engrafted in the lungs of mice
[68]
.   
On the other hand, antibodies targeting the β7 integrin, found on the surface of inflammation associated 
helper T cells, were covalently attached to lipid-based nanoparticles and used to selectively deliver 
siRNA specific for the cyclin D (CyD1) (a cell cycle regulatory molecule) gene to the target cells to 
knock down the protein
[69]
. Following intravenous administration this approach resulted in a reduction of 
intestinal inflammation in a mouse model
[69]
. In a separate approach the efficacy of self-assembling 
nanoparticles containing siRNA and constructed from polyethylenimine (PEI), PEG and a peptide ligand 
to target integrins found in tumour neovasculature were investigated
[70]
. These were used to successfully 
target vascular endothelial growth factor-receptor 2 (VEGF-R2) and thus inhibit tumour angiogenesis 
and growth rate
[70]
. 
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Another targeting ligand of particular interest is the transferrin receptor (TfR), which is overexpressed in 
many cancer tissues
[71]
. A number of different polymers have been modified to target transferrin 
including cyclodextrins
[72]
 and liposomes
[63, 64, 73]
. Martlett and Davis
[72] 
have shown activity of 
transferrin (Tf)-targeted siRNA-cyclodextrin particles against ribonucleotide reductase subunit 2 
(RRM2) in a murine tumour model. Alternatively, PEGylated immunoliposomes modified with two 
monoclonal antibodies against the mouse TfR and the human insulin receptor were able to cross the 
blood brain barrier, via the TfR and once inside the compartment were able to enter brain tumour cells 
via the insulin receptor and resulted in a prolongation of survival
[73]
.  
Since its discovery, the folic acid receptor (FR) and its expression has been extensively characterised. 
There are five isoforms of the receptor, ’ and The  form of the receptor is upregulated in 
many forms of cancer including ovarian, lung, breast, kidney, brain and colon
[74]
 while expression in 
normal tissues is minimal. The non-epithelial isoform FRβ is expressed on activated macrophages found 
in arthritic joints and a host of other inflammatory diseases such as, psoriasis, systemic lupus 
erythematosus and ulcerative colitis
[74]
.  Zhang et al.
[75]
 demonstrated the cell specific uptake of siRNAs 
which were noncovalently attached to folate-conjugated oligodeoxynucleotides (ONDs) in vitro to cells 
overexpressing FRα. Furthermore, FR-dependent silencing of αV integrin in human umbilical vein 
endothelial cells (HUVEC) and of survivin (an apoptosis inhibitor gene) in human nasopharyngeal 
carcinoma (KB) cells has been demonstrated
[75]
. An advantage to the use of folic acid is the relative ease 
with which it can be conjugated to both therapeutic and diagnostic agents 
[76]
.  
The sigma receptor, a membrane bound protein showing high affinity for antipsychotic drugs, although 
expressed on some normal tissues such as the brain,  is overexpressed on a range of tumours including, 
melanoma, prostate and non-small cell lung tumours
[77-80]
.  Banerief et al.
[77] 
first demonstrated the use of 
the selective sigma ligand namely anisamide to mediate efficient targeting of liposomal drugs to sigma 
receptor-expressing prostate cancer cells in vitro and in vivo. Since then there have been several articles 
reporting the application of anisamide targeting nanoparticles for the cell specific delivery of therapeutic 
siRNA
[78-80]
.  
The asialoglycoprotein receptor is expressed on hepatocytes and is able to recognise the galactose units 
on the oligosaccharide chains of glycoproteins or on chemically synthesised galactosylated carriers
[81, 82]
. 
Thus siRNAs complexed with galactosylated cationic liposomes can be used as a specific targeting tool. 
For example, systemic administration of such complexes was directed specifically towards liver 
parenchymal cells and produced a knockdown of the endogenous gene Ubc13
[81]
.  In the treatment of 
hepatitis C (HCV) it is essential that any treatment is specifically targeted to the liver. Lactosylated 
cationic liposomes intravenously administered to mice accumulated primarily in the liver throughout the 
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hepatic parenchymal cells. The inclusion of anti-HCV siRNA in the targeted liposomes led to a dose-
dependent suppression of intrahepatic HCV expression
[82]
. 
Intracellular barriers to siRNA delivery 
Endolysosomal escape. Having generated siRNA-delivery vectors which successfully overcome the 
abovementioned challenges, the complexes are ready for internalization by the cells of interest in which 
even further barriers await. Untargeted cationic polyplexes bind to the surface of cells via electrostatic 
interaction and are generally internalized through adsorptive pinocytosis (a process of taking in fluid 
together with its contents into the cell)
[83]
. Alternatively, polyplexes modified with targeting ligands bind 
to the specific cell-surface receptors and enter into cells by receptor-mediated endocytosis
[84]
. In either 
pathway, the polyplexes become entrapped inside the endososomes, which represent a hostile 
environment
[84]
. Once inside the early endosomes, the internalized material can be transported back to 
the membrane and out of the cell by exocytosis. More commonly however, polyplexes are considered to 
be transported to late endosomes in which the pH quickly drops to ~5-6. Polyplexes can subsequently be 
delivered into lysosomes in which the pH further decreases to ~4.5 and there are a variety of degradative 
enzymes awaiting
[84]
. Unprotected nucleic acids entrapped in these vesicles are eventually degraded. 
Only siRNA that escapes intact from the endosomes/lysosomes can arrive safely at the cytoplasm to 
enter into the RNAi pathway.  
Several approaches have been employed to overcome the endo-lysosomal barrier. Chloroquine is a 
buffering agent known to disrupt the endosomal membrane by raising the pH of the endosome 
environment. Chloroquine when simultaneously added to cells at the time of transfection results in 
enhanced gene transfection with some polymers
[85]
. Although this strategy has been commonly used in 
vitro, it is impractical for in vivo gene delivery due to its toxicity
[86]
. Additionally, inactivated adenovirus 
particles tethered to polylysine achieved up to a 2000-fold gene transfer
[87]
 possibly due to virus-induced 
endosomal escape. This method is also impractical in vivo due to the increased difficulty of preparing the 
vector and safety issues, especially immunogenicity and mutagenesis. Alternatively, fusogenic viral
[88]
 or 
synthetic
[89]
 peptides can be attached to various polymers to assist endosomal escape. These peptides are 
normally pH-triggered amphiphiles that undergo a structural change in the acidic environment and then 
burst the vesicle membrane. Finally, certain materials, such as PEI and polyamidoamine (PAM), can 
escape from endosomes by what has been referred to as the ‘proton-sponge hypothesis’ by which the H+ 
buffering capacity of polyamines results in endosomal Cl
-
 accumulation during acidification resulting in 
osmotic endosome swelling and enhanced polyplex escape
[90]
. 
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Gene-unpacking. Once released from the endosomal compartments, poleplexes must subsequently 
dissociate from the siRNA at some point in the cytoplasm for entering into the RNAi pathway. Much of 
our understanding of this process comes from investigations with plasmid DNA. Several studies have 
found that gene expression is improved by reducing the number of positive charges
[91]
, conjugation of 
PEG chains
[92]
, or decreasing the polymer molecular mass
[93]
. Therefore, synthetic vectors must clearly 
be designed to incorporate a mechanism for nonspecific or environmentally responsive release of siRNA. 
 
Physiochemical characterization and formulation of delivery vehicles  
Several physical factors, including the size, charge and ability to complex or encapsulate the siRNA, 
have been shown to influence the efficacy of non-viral delivery systems
[48, 54]
. The size of particles for 
use as delivery vectors can be modified during the formulation process. Small particles (with diameter 
less than 500nm, usually <150nm) have an enhanced permeation and retention (EPR) in inflammation 
sites and solid tumours due to the leaky vasculature and endothelial junctions in those tissues
[54]
. An 
additional vital characteristic of the delivery vector is the surface charge. As described earlier, a positive 
charge will promote serum instability and non-specific interactions with both target and non-target cells. 
As outlined previously, PEG is often used to shield cationic surface and additionally act to prevent 
aggregation of the delivery vehicles and improve in vivo circulation. Encapsulation efficiency of 
nanoparticles can be increased using detergent or ethanol dialysis
[54]
. Formation of nanoparticles can be 
controlled by adjusting the concentration, charge ratio, ionic strength of solutions and rate of mixing
[54]
. 
The ratio of lipid/siRNA used is also an important factor found to affect transfection by influencing the 
particle size of the constructs
[54]
. The aqueous medium in which the lipid/siRNA complex forms 
influences the degree of transfection
[94]
. By using OptiMEM medium rather than water for the dilution of 
liposomes and siRNA and their mixing, significantly improved gene knockdown was generated
[94]
.  
Taking all of the abovementioned considerations, both biological and physicochemical, into account one 
can speculate on the ideal properties of a non-viral delivery system. These are outlined in Figure 2 and 
include biological stability, nanosized particles and cell-specific targeting. The achievement of these 
properties is dictated by the selection of materials, the formulation method used and the eventual 
therapeutic application.  
======================================================= 
Insert Figure 2 about here 
====================================================== 
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In the light of the wide permutations of synthetic non-viral vector systems that have emerged over the 
last decade, Kostarelos and Miller
[95]
 introduced an interesting and rational classification system to aid in 
the selection and comparison of the different technologies available. This ABCD concept is thus an 
appropriate structural paradigm for modified polymer-based carrier systems employed for in vitro, ex 
vivo and/or in vivo application. In ABCD nanoparticles [Figure 3], nucleic acids (termed A) are generally 
condensed within functional concentric layers of polymeric components that help cellular 
entry/intracellular trafficking (termed B); this is subsequently modified by addition of a biological 
stability group (termed C), and a distal biological targeting ligand (termed D). A variety of siRNA 
delivery systems will now be reviewed based on this ABCD concept.  
 
 
======================================================= 
Insert Figure 3 about here 
======================================================= 
“A”system - based delivery 
Several studies have shown that delivery to certain tissues, such as the eye
[96, 97]
, lung
[98]
, liver
[99]
, 
limb
[99]
 and central nervous system (CNS)
 [100, 101]
 of ‘naked’ siRNA is effective. The term ‘naked’ 
siRNA refers to the delivery of siRNA (unmodified and modified) in saline or in simple excipients such 
as a solution of 5% dextrose in water (D5W). In a laser-induced choroidal neovascularisation in a non-
human primate model of age–related macular degeneration (AMD) intravitral injection of saline-
formulated vascular endothelial growth factor (VEGF) siRNA was well tolerated and efficient
[96]
. 
Intravitreal injection of saline-formulated siRNA targeting VEGF receptor-1 was also effective in 
reducing the area of ocular neovascularisation in two different mouse models
[97]
. siRNA formulated in 
D5W administered intranasally in a non-human primate model of severe acute respiratory syndrome 
(SARS) corona virus infection significantly reduced interstitial infiltrates and pathological changes, and 
inhibited viral replication in the lung
[98]
. The first report showing siRNA transfer into selected grafts 
(liver and limb) was achieved by a catheter-based intravenous rapid-injection method
[99]
. Hydrodynamic 
delivery involves injection of a large volume of nucleic acid solution and this rapid and large volume 
injection of solution exceeds the cardiac output and causes a transient overflow in the inferior vena cava, 
which induces nucleic acid solution to flow into the liver. This is followed by a quick increment of intra-
hepatic pressure, liver expansion and reversible disruption of the liver fenestrae. This approach may be 
applicable to humans by using balloon catheter-based and occlusion-assisted injection to a specific vein 
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of an expandable organ
[102]
. The modification of balloon catheters and the development of a minimally 
invasive technique to allow selective isolation of liver segments for hydrodynamic gene therapy in the 
animals and humans are promising for siRNA specific-delivery
[102]
. Direct administration of siRNA in 
saline has also been utilized in the CNS to confirm disease targets in vivo. Direct instillation of saline-
formulated siRNA by intracerebroventricular, intrathecal or intraparenchymal infusion led to silencing of 
specific neuronal mRNA targets in multiple regions of the peripheral and central nervous system
[100, 101, 
103]
. 
The application of unmodified siRNA for therapeutic use has been demonstrated in certain tissues; 
however, for more general use the transfection efficiency of unmodified siRNA is too low (see above 
discussions). Besides, unmodified siRNA is susceptible to attack from serum enzymes and is apt to 
induce off-target effects. As mentioned earlier, siRNA modifications to improve transfection or a 
delivery vehicle are required to overcome the issues. siRNA bearing 3’overhangs of two P=S 2’-O-(2-
methoxyethyl)-ribonucleotide and targeting the pain related cation-channel P2X3 intrathecally 
administered to rats resulted in pain relief demonstrated by inhibition in the neuropathic pain 
response
[104]
. siRNA stability in the extracellular and intracellular environments can be enhanced by 
modifying the oligo backbone and replacing individual nucleotides with analogues. Administration of 
this chemically modified siRNAs resulted in silencing of the apolipoprotein B (apoB) messenger RNA in 
the liver and jejunum, decreased plasma levels of apoB protein, and reduced total cholesterol
[37]
.  
The ease of formulation and administration using direct delivery of naked siRNA to tissues make this an 
attractive therapeutic approach. However, the naked uncomplexed siRNA dose that is typically required 
for target silencing in these studies is high and siRNA uptake is uneven increasing the risk of off-target 
effects and toxicity. Moreover, systemic delivery is more feasible where the disease site is not easily 
accessible and intravenous or intraperitoneal (i.p.) treatments are required. Therefore, it is sometimes 
essential to formulate siRNA with a transfection reagent or a specialized delivery system. 
“AB” system - based delivery 
AB particles are generally formed by the condensation and/or encapsulation of nucleic acids using 
cationic polymers (B-layer). When lipids condense with nucleic acids to form shapeless particles, for 
example, they are named as lipoplexes. Lipoplexes are formed by simply mixing siRNAs with most 
commercial transfection reagents, including Lipofectamine™ 2000 (Invitrogen) and Transit-TKO® 
(Mirus). Intranasal administration of siRNAs complexed with/without the transfection agent Transit-
TKO® against viral genes decreased the viral load of respiratory syncytial virus (RSV) and 
parainfluenza virus (PIV)
[105]
. It suggests that, if properly designed, low dosages (as low as 70µg per 
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animal) of inhaled siRNA might offer a fast, potent and easily administrable antiviral regimen against 
respiratory viral diseases in humans without any adverse events. Moreover, a rational approach to deliver 
siRNA has been recently designed using cationic lipids
[169]
. The AB formulation was started with the 
ionizable cationic lipid 1, 2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), a key lipid component 
of stable nucleic acid lipid particles (SNALP) as a vector
[169]
. The results have shown that this 
DLinDMA-based formulation achieved superior in vivo siRNA delivery capacity using either the rodent 
model or the nonhuman primate models
[169]
.  
In addition, protein transduction domains (B-layer) are short amino acid sequences that interact with the 
plasma membrane of a cell in a receptor-independent manner that results in efficient cellular uptake
[106]
. 
Fusiogenic peptides based on those found in the fusion domains of the Influenza A virus have been 
synthesised and shown to be effective in the in vitro delivery of siRNA, the enhancement of endosomal 
escape and the silencing of the oncogene EGFR
[106]
. Only short sequences of primarily positively 
charged amino acids (arginine and lysine) are responsible for the translocation through the membrane. 
Cell penetrating peptides (CPPs) may be used to transfect a range of different cell types with high 
efficiency
[107]
.  
“AD” system - based delivery 
Conjugation of siRNAs to a targeting molecule (D-layer) has been used to delivery siRNA into cells and 
can be employed for cell-specific targeted delivery. Conjugation is particularly attractive for siRNA-
based therapeutics since only one of the strands in the duplex is functional and conjugates can be 
attached to either the sense or antisense strand without compromising the activity of the silencing. A 
peptide mimetic of insulin-like growth factor 1 (IGF1) conjugated to siRNA and directed to insulin 
receptor substrate 1 (IRS1) protein, increased the in vitro cellular uptake of siRNA in comparison to 
unconjugated siRNA
[108]
.   
Aptamers, peptide molecules that bind to specific target molecules, can be synthesised and subsequently 
utilised for the cell specific delivery of siRNAs
[109, 110]
. Both components can be chemically synthesised 
so aptamer-siRNA conjugates have the potential to be applied to a wide range of diseases. Chu et al.
[109] 
demonstrated that an anti-prostate specific aptamer (PSMA) coupled via a streptavidin bridge with 
siRNA against lamin A/C, could be used to specifically and efficiently deliver functional siRNA to 
PSMA positive cells in vitro.  Similarly PMSA conjugated siRNA targeting the survival gene PLK1 has 
been used in vivo to induce regression of PMSA expressing LNCaP induced prostate tumours
[110]
. 
Wolfrum et al.
[111] 
demonstrated that cholesterol-conjugated siRNA is taken up in murine models by a 
lipoprotein-dependent mechanism. Delivery of the siRNA conjugates depended upon interactions with 
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lipoprotein particles, lipoprotein receptors and transmembrane proteins.  siRNA delivery was directed 
towards the liver, gut, kidney and steroidogenic organs by high density lipoproteins whereas low density 
lipoproteins targeted siRNA to the liver. 
A particularly challenging area is delivery to the brain across the blood brain barrier. Kumar et al.
[112]
 
showed that a short peptide derived from rabies virus glycoprotein (RVG) enables the transvascular 
delivery of siRNA to the brain. To enable siRNA binding, a chimeric peptide was synthesized by adding 
nonamer arginine residues at the carboxy terminus of RVG, which specifically bound to the nicotinic 
acetylcholine receptor expressed by neuronal cells
[112]
. After intravenous injection into mice, this system 
delivered siRNA to neuronal cells, resulting in specific gene silencing within the brain and robust 
protection against fatal viral encephalitis in mice
[112]
. 
It has recently been shown that siRNA synthetically conjugated to a CpG oligonucleotide agonist of the 
TLR9, targeted and silenced the signal transducer and activator of transcription 3 (STAT3, an immune 
suppressor gene) in TLR9 (+) myeloid cells and B cells
[113]
. STAT3 has been reported to orchestrate the 
expression of immunosuppressive and angiogenic factors, contributing to a tumour environment 
characterized by a lack of tumour-specific cytotoxic T cells and an inhibition of T helper 1 (TH1) 
cells
[113]
. Silencing of STAT3 using CpG-linked siRNA by either local delivery at the tumour site or 
intravenously injection in a mouse model led to activation of tumour-associated immune cells, triggering 
of  antitumour immune responses and eventual inhibition of tumour growth
[113]
.  
“ABC” system - based delivery 
Due to the C component, the addition of stealth/biocompatable polymers, formulations of this type 
appear to be very promising for systemic applications and gene therapy due to improved serum stability 
in comparison with AB systems
[95]
. ABC particles are especially beneficial for passive targeting 
delivery, in light of the leaky endothelial wall (~400nm) in inflammatory and tumour sites resulting in 
the EPR effect as described above. Kim and colleagues
[114]
 utilized PEG-conjugated VEGF siRNA 
(siRNA-PEG) and PEI to spontaneously form nanoscale polyelectrolyte complex micelles, having a 
siRNA/PEI inner core with a surrounding PEG shielding layer. Intravenous administration of this 
formulation successfully inhibited VEGF expression and tumour development in a tumour-bearing 
mouse model. In addition,  a systemic siRNA delivery approach based on a novel lipid-like material 
(98N12-5(1)), cholesterol, PEG-lipid and modified siRNA has been recently developed
[115] 
. This ABC 
system was able to target the liver (>90% distribution) and induce reversible, long-lasting gene silencing 
without any loss in activity following repeated administration, possible orchestrated by the fact that 
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smaller particles would have efficient access to hepatocytes via the fenestrated endothelium of liver 
(~100nm).  
However, as PEGylation may shield the cationic surface of formulations, the EPR effect achieved results 
in good permeability but poor retention for small particles without a targeting ligand. One approach that 
has been developed to combat this is the addition of a novel pH-sensitive benzoic imine linker between 
the PEG group and the polymer (e.g. poly-l-lysine)
[116]
. The linkage is stable in aqueous solution at 
physiological pH (pH ~7.4) but cleaves in acidic conditions such as the extracellular environment of 
solid tumour (pH ~6.8) and in endosomes (pH ~5.5). When this formulation arrives at the tumour sites 
via EPR effect, the cationic surface becomes exposed. This is driven by the reversible detachment of the 
shielding PEG chains due to the processing of the imine linkage, resulting in binding of vectors to the 
tumour tissues by electrostatic interaction and enhancement of endosomal escape
[116, 117]
. 
“ABD” system - based delivery 
Some attractive examples of ABD particles, in addition to those described in the cell-specific targeting 
section above,  have recently emerged and these appear to be particularly effective for in vivo studies, 
although they can be somewhat irregular in formulation
[95]
. Liposomes for instance, can fuse with 
biological membranes and enhance drug delivery into cells. Liposomes employed for therapeutic 
delivery are composed of many components, including a variety of lipids, such as cationic and/or 
fusogenic lipids, cholesterol and helper lipids
[54]
. Liposomes with targeting moieties have been 
developed to improve cell specific uptake of siRNA
[118, 119]
. In this context, Vitamin A-coupled 
liposomes successfully delivered therapeutic siRNA targeting gp46 (a rat homolog of human heat shock 
protein 47 which is crucial for cellular stress response) to prolong the survival in a rat model of lethal 
liver cirrhosis
[118]
. The efficacy of this approach has been expanded to both acute and chronic models of 
liver fibrosis and suggests its therapeutic potential for reversing human liver cirrhosis
[118]
.  
In the context of CNS delivery, siRNA was administered into the brain in vivo with the combined use of 
a receptor-specific monoclonal antibody delivery system, and in this case liposome technology was 
replaced by avidin-biotin technology
[119]
. It suggests that brain delivery of siRNA following intravenous 
administration is possible with siRNA and appropriate targeting vectors. 
 Moreover, a newly developed ABD system has been shown successfully to deliver siRNA to 
macrophages through oral administration, resulting in suppression of inflammation responses and 
increased survival rates in mice
[120]
. In this study, siRNA was condensed with PEI and the “siRNA-PEI” 
layer was encapsulated inside β 1, 3-D-glucan particles[120]. These particles directed phagocytosis by 
macrophages and dendritic cells by means of the dectin-1 receptor (a major beta-glucan receptor) and 
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perhaps other β 1, 3-D-glucan-receptor-mediated pathways[120]. This technology offers an exciting and 
novel strategy for oral delivery of siRNA to attenuate inflammatory responses in human disease. 
“ACD” system - based delivery 
Using a previously designed AD delivery system appended with a PEG moiety
[110]
, a novel ACD particle 
has recently been successfully developed
[121]
. Researchers have enhanced the silencing activity and 
specificity of the aptamer-siRNA chimera by incorporating modifications that enable more efficient 
processing of the siRNA by the cellular machinery. These complexes resulted in significant inactivation 
of PSMA-expressing tumours in an athymic mouse model by intravenous administration. More 
importantly, the in vivo circulating half-lives of the chimeras were dramatically increased from <35min 
to >30hour by the addition of the PEG group
[121]
.  
“ABCD” system – based delivery 
For most systemic applications and gene therapies, the entire ABCD class of particles is possibly the 
most desired strategy. The number of novel ABCD systems is increasing despite the different technical 
barriers in developing reproducible and scalable formulations of an AB core coupled with the controlled 
and consistent association of C and D layer components. As these ABCD formulations are nearly neutral 
or even negative in charge, the remarkable gene silencing data when administered systemically must be a 
result of active cell-specific targeting. Li and colleagues developed a nanoparticle formulation for 
successfully systemic delivery of siRNA into xenograft
[122, 80]
 and metastatic tumours
[78, 79]
 which 
produced anti-cancer effects. In this system, the nucleic acids (siRNAs and carrier DNA), a polycationic 
peptide (protamine) and a cationic liposome, were initially prepared in a condensed core. The resulting 
core was then modified by PEG-lipid containing the tumour targeting ligand, anisamide (see above) 
[78-
80]
. The resulting targeted nanoparticles silenced the epidermal growth factor receptor (EGFR) in the 
tumour and induced ~15% tumour cell apoptosis without any indication of immunotoxicity
[122]
. In a 
mouse model of metastasis, a mixture of siRNA against the cancer associated proteins MDM2, c-myc, 
and VEGF, co-formulated in the targeted formulation, administered intravenously caused simultaneous 
silencing of each of the genes. Importantly, the targeted nanoparticles at the therapeutic dose used, 
showed little local and systemic immunotoxicity, body weight alterations or damage to the major 
organs
[78]
. 
In addition, as described earlier Peer et al.
 [69]
 developed a strategy for selectively silencing CyD1 in 
leukocytes in vivo. Liposomes were grafted with a spacer namely hyaluronan (a high-molecular-mass 
polysaccharide) to the outer surface, thus stabilizing the particles both during subsequent siRNA 
entrapment and during systemic circulation in vivo. The resulting particles were successfully modified 
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with a targeting ligand by covalently attaching a monoclonal antibody to hyaluronan. Targeted stabilized 
nanoparticles (tsNPs) were eventually loaded with CyD1-siRNA. The antibody was specific to direct 
particles to β7 integrins overexpressing in gut mononuclear leukocytes. Systemic application of β7 
integrin-tsNPs silenced CyD1 in leukocytes and reversed experimentally-induced colitis in mice
[69]
. This 
research further identifies CyD1 as a potential anti-inflammatory target, and suggests that the application 
of similar modes of targeting of siRNA may be applicable in other therapeutic settings and for further 
target validation efforts.  
Some of the most novel areas of development of ABCD vectors are those employing cyclodextrins
[72, 123-
125]
. Cyclodextrins are natural cyclic oligosaccharides composed of 6, 7, or 8 D(+)-glucose units known 
as and respectively. The geometry of cyclodextrins gives a hydrophilic outer surface and 
hydrophobic inner cavity into which it is possible to fit insoluble molecules to form inclusion complexes. 
Davis and colleagues have developed a novel ABCD system based on i) condensation of siRNA with 
cyclodextrin-containing polycations (CDPs), and, ii) modification of the CDP-siRNA by forming 
inclusion complexes with adamantane (a hydrophobic molecule) which in turn is utilised for the 
attachment of the functional groups PEG-transferrin . This formulation has indicated efficacy in the 
delivery of the siRNA against oncogene to inactive the tumour growth in a murine model of metastatic 
Ewing’s sarcoma[124].  Three continuous daily doses of the CDP-siRNA-adamantine-PEG-transferrin 
formulation carrying two types of siRNAs specific for the gene encoding ribonucleotide reductase 
subunit M2 (RRM2) slowed tumour development, whereas non-targeted formulations were dramatically 
less effective when administered under the same conditions
[72]
. 
An alternative strategy uses cyclodextrins as potential core molecules which can be modified directly 
with various functional groups including; polycations, lipophilic chains (amphiphilic vectors), PEG 
chains and targeting ligands
[126-129]
. Amphiphilic cyclodextrins have been shown to form vesicles with 
the potential to encapsulate siRNA inside the aqueous core
[126, 130, 131]
. The structural concept of 
cyclodextrin:siRNA vesicles is illustrated in Figure 4. There are many advantages associated with this 
approach, as oligosaccharides they have low immunogenicity and the availability of multiple sites for 
attachments of functional groups confers flexibility to accommodate the targeting requirements for a 
range of therapeutic applications. In essence, this technology has the capacity to form nanosized, neutral, 
cell specific transfection systems compliant with the ‘ideal’ properties as outlined in Figure 2. 
======================================================= 
Insert Figure 4 about here 
======================================================= 
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In addition to the ABCD concept described above, general summaries of the major delivery strategies 
including disease, gene target and delivery method used in vitro and in vivo are given in Table 1 and 
Table 2 respectively.  
 
Clinical Trials 
A number of siRNA therapies have advanced into clinical trials, a summary of these on-going trials is 
provided in Table 3.  Given the ease of access to the eye and that the use of naked siRNA is effective in 
these cases, the most progress to date is in the treatment of eye diseases
[132]
. Age-related macular 
degeneration (AMD), a progressive condition leading to impaired central vision is currently the subject 
of several clinical trials. The condition is characterised by the growth of abnormal leaky blood vessels 
beneath the macula that damages the area of the eye essential for fine-detail vision. All trials involve the 
direct injection of siRNA into the macular of the eye. However, Allergan halted development of its 
AGN211745, a chemically modified siRNA after the drug failed to meet a key efficacy endpoint in a 
phase II study (www.allergan.com). No safety issues were associated with AGN211745 targeting VEGF-
1. But since the drug did "not meet its efficacy hurdle", Allergan opted to halt its development 
(www.allergan.com). Additionaly, OPKO Health, Inc. has decided to terminate its Phase III clinical 
study of Bevasiranib (a naked siRNA) for the treatment of AMD (www.opko.com). Although there were 
no systemic safety issues identified and local ocular safety was generally unremarkable, review of the 
data indicated that the trial, as structured, was unlikely to meet its primary end point (www.opko.com). 
QPI-1002, the first systemically administered siRNA drug developed by Quark Pharmaceuticals, Inc., is 
currently being evaluated in a Phase I/IIa clinical trial study for the prevention of acute kidney injury 
(AKI) and also in a Phase I/II clinical trial for the prophylaxis of delayed graft function (DGF) following 
renal transplantation (www.quarkpharma.com). Treatment of the respiratory disease respiratory syncytial 
virus (RSV) using nebulised delivery of naked siRNA has progressed to Phase II. The highly contagious 
RSV causes infections in both the upper and lower respiratory tract. Interim reports suggest that subjects 
receiving the drug ALN-RSV01 administered by nebulisation and targeting the RSV nucleocapsid 
experienced a 38% reduction in infection rates (www.alnylam.com). This was in conjunction with an 
increase in the number of subjects who remained free of infection (www.alnylam.com). Pachyonychia 
congenital, a rare keratin disorder that affects the nails, skin, oral mucosae, larynx, hair and teeth has 
been associated with mutations in the N171K gene. Patients can suffer from painful blisters and 
keratoderma with no disease specific treatment currently available
[133]
. In association with the 
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Pachyonychia Congenita Project, TransDerm are performing a clinical trial into the effectiveness of 
TD101, an siRNA targeting mutations in N171K and more specifically the keratin K6a
[133]
.  Initial trials 
involve the local injection of siRNA into the foot with a view to developing a gene cream for topical 
application (www.transderm.org).  
An ABCD delivery system
 
currently undergoing clinical trials utilises the RONDEL
TM
 
(RNAi/Oligonucleotide Nanoparticle Delivery) technology developed by Calando Pharmaceuticals. 
Their targeted nanocomplex, composed of transferrin targeted cyclodextrin containing polycations and 
anti RRM2 siRNA (CALAA-01), yielded promising results in mouse models
[72]
. CALAA-01 has 
advanced to phase I clinical trials in the treatment of solid tumours to determine the safety and maximum 
tolerated dose of the ‘drug’ when administered intravenously to patients. It was announced recently that 
in addition to CALAA-01, pre-clinical development of a second siRNA oncology therapeutic is 
underway (www.calandopharma.com). CALAA-02 uses the same delivery system as CALAA-01, but 
will target hypoxia inducible factor-2 (HIF-2), which is over-expressed in many solid tumours and 
has a role in tumourigenesis
[134]
. 
An interventional clinical trial that is for Metastatic Melanoma and absence of CNS metastases 
conditions was started in January of 2008 in Duke University. Transfection with siRNA targeting the 
immunoproteasome alters proteasome-mediated antigen processing by the dendritic cell, resulting in a 
reduction of enhanced anti-melanoma immune responses (www.cancer.duke.edu). This Phase I trial, 
open to subjects with metastatic melanoma, will assess the safety of vaccination with melanoma tumour 
associated antigen-encoding RNA-transfected mature dendritic cells derived from monocytes that have 
been either untreated, transfected with control siRNA, or transfected with siRNA targeting the inducible 
immunoproteasome (www.cancer.duke.edu). As a secondary objective, this Phase I study will also assess 
the anti-melanoma immune responses, as well as clinical responses, induced by vaccination with this 
dendritic cell-based product. 
 
 
Conclusion 
The use of synthetic siRNA as a therapeutic to knockdown the expression of a gene or protein has 
generated huge interest in both the scientific and business communities. It has the potential to be utilised 
in a diverse range of disease states, including cancer, cardiovascular disease, inflammatory conditions, 
viral infections and CNS disorders. Despite the identification of numerous gene targets for these 
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conditions (Table 1 and Table 2) the main impediment to the use of siRNA therapeutically is the 
achievement of safe and efficient delivery.  
The rate of progress in the delivery dilemma has nonetheless been remarkably rapid and the future is 
likely to reside with the development of non-viral systems due to the decreased risk of toxicity compared 
to viral-based systems. However, as can be seen from the current clinical trial studies described above 
most involve naked or chemically modified siRNA, the Calando trial is the only formulated product, it is 
the first and so far the only trial ongoing for treatment of solid tumours. Consequently, opportunities 
exist to develop further innovative delivery technologies to satisfy the enormous unmet need in this field. 
Given the requirement for cell-specific delivery of therapeutic siRNA, justifiable consideration is being 
given to the design and formulation of targeted, non-immunogenic and efficient delivery technologies, 
such as described by the ABCD vector strategy. By driving this promising approach forward the gap 
between concept and clinic will potentially be bridged heralding a new era of joy, the silent era resulting 
in the availability of gene-based medicines.  
 
 24 
Table 1. A summary of studies on the in vitro delivery of siRNA, including the delivery method, the target gene and the therapeutic target. 
Delivery system Therapy Target(s) Comments References 
Conjugated 
siRNA 
LNCaP cells 
(Prostate Cancer) 
Lamin A/C Aptamer:streptavidin:siRNA conjugates [109] 
Conjugated 
siRNA 
LNCaP cells 
(Prostate Cancer) 
Bcl-2 
PLK1 
Aptamer:siRNA chimeras [110] 
Conjugated 
siRNA 
CEM cells 
(HIV) 
Anti tat/rev Anti gp120 aptamer:siRNA conjuates [135] 
Peptide 
MCF-7 cells 
(Breast Cancer) 
IRS-1 IGF1 peptide mimetic conjugated to siRNA [108] 
Peptide 
HS-68 cells (fibroblasts) 
HeLa cells (Cervical Cancer) 
N/A fluorescent 
siRNA and 
Luciferase (reporter) 
Cell penetrating peptide  [107] 
Peptide Dorsal root ganglion cells p75
NtR
 Histidine rich reducible polycations [136] 
Peptide 
A431 cells 
(epidermoid carcinoma) 
EGFR 
Influenza derived fusogenic peptide diINF-
7/Lipofectamine/siRNA 
[106] 
Peptide 
C26 cells 
(Colon Cancer) 
K-ras 
Influenza derived fusogenic peptide diING-
7/Lipofectamine/siRNA 
[106] 
Liposomes 
PANC-1  
(Pancreatic Cancer) 
MDA-MB-435 (Breast Cancer) 
HER-2 Immunoliposomes [64] 
Liposomes 
SK-MES-1 cells 
(Lung Cancer) 
HDM2 
Liposomes modified with arginine octamer 
molecules 
[137] 
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Liposomes 
Hepatic Stellate cells 
(Liver Cirrhosis) 
gp46 (rat homolog of 
human HSP47) 
Lipotrust cationic liposomes coupled with 
vitamin A 
[118] 
Lipoplexes 
Hela cells 
SW756 cells 
(Cervical Cancer) 
E6 Oligofectamine [138] 
Lipoplexes 
HeyA8 and SKOV3ip1 cells 
(Ovarian Cancer) 
IL-8 RNAiFect  [139] 
Lipoplexes 
Fibroblast like synoviocytes 
(Rheumatoid Arthritis) 
PARP-1 DharmaFECT 1 [140] 
Lipoplexes Human Mesenchymal Stem Cells EGFP (reporter) 
Lipofectamine 2000, RNAiFect, RiboJuice, 
GeneEraser and siPORT 
[141] 
Lipoplexes Parkinson’s disease LRRK2 Nucleofection Kit (Amaxa)  [142] 
Lipoplexes 
Vascular Smooth Muscle Cells 
(Cardiovascular Disease) 
Ki-ras2A Lipofectamine Plus [143] 
Lipoplexes 
HEK293 
(Alzheimer’s Disease) 
TMP21 
Cells stably transfected with PS2, siRNA 
transfected using Lipofectamine 2000 
[144] 
Lipoplexes 
HeLa cells 
(Polio) 
siC (capsid) 
siP (viral polymerase) 
Lipofectamine 2000 [145] 
Nanoparticles 
HeLa cells  
(Cervical Cancer) 
EGFP (reporter) 
Quantum dots conjugated to peptide and 
siRNA 
[146] 
Nanoparticles 
H1299 cells  
(Lung Cancer) 
EGFP (reporter) Chitosan/siRNA nanoparticles [147] 
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Nanoparticles Cardiomyocytes ERK1/ERK2 Single walled carbon nanotubes [148] 
Nanoparticles 
PC-3 
(Pancreatic cancer) 
VEGF 
Thermally sensitive cationic polymer 
nanocapsules 
[149] 
Nanoparticles 
FL5.12A IL-3 dependent  pro B cells 
D1 IL-7 dependent cells 
Survivin Bacteriophage phi29 pRNA nanoparticles [150] 
Cyclodextrins 
HeLa cells 
(Cervical Cancer) 
Luciferase (reporter) Cyclodextrin containing polycations [151] 
Cyclodextrins 
N2A cells 
(Neuroblastoma) 
RRM2 
Transferrin targeted cyclodextrin containing 
polycations 
[72] 
Polymers 
MCF-7 cells 
(Breast Cancer) 
sCLU PEG-PEI –siRNA polymer complexes [152] 
Polymers 
PC-3 cells 
(Prostate Cancer) 
VEGF VEGFsiRNA-PEG-PEI [114] 
Gel-based 
medium 
 
(Colorectal Cancer) 
Bcl-2 Agarose/liposome/siRNA  [153] 
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Table 2. A summary of studies on in vivo delivery of siRNA, including the delivery method, the target gene, the therapeutic target and the route of administration. 
 
Delivery 
system 
Therapy Target(s) Comments Route of Administration References 
Naked siRNA Pulmonary Alveoli GAPDH (reporter) Naked siRNA Administered intranasally [154] 
Naked siRNA Limbs Luciferase (reporter) Naked siRNA 
Luciferase siRNA administered via 
the great saphenous vein of mouse 
[155] 
Naked siRNA Liver and Limbs GFP (reporter) Naked siRNA Catheter-based injection [99] 
Modified 
siRNA 
Chronic Neuropathic 
Pain 
P2X3 Naked siRNA Administered intrathecally [104] 
Conjugated 
siRNA 
LNCaP tumours 
(Pancreatic Cancer) 
PLK-1 
Aptamer:siRNA 
chimeras 
Administered intratumourally [110] 
Conjugated 
siRNA 
HIV CCR5, Vif, Tat 
Anti-CD7 antibody 
conjugated to siRNA 
Administered via i.v. [67] 
Protein Bone metastasis 
EZH2 
p110- 
Atelcollagen/siRNA 
complexes 
Administered via the tail vein [156] 
Peptide Eye 
N/A 
Lissamine 
conjugated peptide 
Peptide for ocular 
delivery (POD) 
complex 
Administered topically to the eye [157] 
Peptide 
Encephalitis 
(Brain) 
Anti viral FvE
1 
Rabies virus 
glycoprotein derived 
peptide/siRNA 
Administered via i.p. [112] 
Liposomes 
HeyA8 or SKOV3ip1 
tumours 
(Ovarian Cancer) 
EphA2 DOPC liposomes Administered via i.v. [158] 
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Liposomes 
Capan-1 tumours 
(Pancreatic Cancer) 
N/A fluorescent 
siRNA  
Cationic 
DOTAP:DOPE 
liposomes (transferrin 
targeted) 
Administered via i.v. [63] 
Liposomes 
HeyA8 or SKOV3ip1 
tumours 
(Ovarian Cancer) 
FAK 
Neutral DOPC 
liposomes 
Administered via i.p. injection [158] 
Liposomes 
HeyA8 or SKOV3ip1 
tumours 
(Ovarian Cancer) 
IL-8 
Neutral DOPC 
liposomes 
Administered via i.p. injection [139] 
Liposomes Hepatitis C GB-virus B Cationic Liposomes Primate model of disease [159] 
Liposomes Bladder Cancer PLK-1 Cationic Liposomes Administered via a catheter [160] 
Liposomes Arthritis TNF- 
DOPE/RPR209120 
cationic liposomes 
Administered via i.v. [161] 
Liposomes Liver  Ubc13 (endogenous) 
Galactosylated cationic 
liposomes 
Administered intraportally or i.v. [81] 
Liposomes 
Liver 
(Hepatitis C) 
Anti HCV 
Lactosylated cationic 
liposomes 
Administered via i.v. [82] 
Lipoplexes 
Hep3B 
(Liver Cancer) 
Rec QL1 DNA 
helicase 
Jet-PEI or Cationic 
liposomes 
Local and systemic delivery [162] 
Lipoplexes 
Inflammatory Bowel 
Disease 
TNF- Lipofectamine  Administered Intrarectally  [163] 
Nanoparticles 
B16F10 tumours 
(Lung Cancer) 
Luciferase (reporter) 
siRNA-Liposome-PEG-
Anisamide particles 
Administered via i.v. [79] 
Nanoparticles 
B16 tumours 
(Lung Metastasis) 
MDM2/c-
myc/VEGF 
siRNA-carrier DNA-
peptide-cationic 
liposome 
Administered via i.v. [78] 
Nanoparticles 
H460 tumours 
(Lung Cancer) 
EGFR 
siRNA-Liposome-PEG-
Anisamide particles 
Administered via i.v. [80] 
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Nanoparticles Lung EGFP (reporter) 
EGFP-transgenic mice 
used 
Chitosan/siRNA particles 
administered intranasally 
[147] 
Nanoparticles 
Inflammatory Bowel 
Disease 
Intestinal Inflammation 
CyclinD1 
Liposome based 
integrin targeted 
nanoparticles 
Administered via i.v. [69] 
Cyclodextrins 
N2A tumours 
(Neuroblastoma) 
RRM2 
Transferrin targeted 
cyclodextrin containing 
polycations 
Administered via the tail vein [72] 
Polymers 
N2A tumours 
(Neuroblastoma) 
VEGF Peptide-PEG-PEI Administered via the tail vein [70] 
Polymers 
PC-3 tumours 
(Prostate Cancer) 
VEGF VEGFsiRNA-PEG-PEI 
Administered intratumourally and 
i.v. 
[114] 
Polymers Systemic Inflammation TNF-/ Map4k4 
siRNA - PEI - β 1, 3-D-
glucan particles 
Oral administration [120] 
Polymers 
Various to determine 
Biodistribution 
EGFR 
PLGA microspheres 
Sustained release 
Administered via i.v. subcutaneously [164] 
Polymers 
S-180 tumours 
(Sarcoma) 
VEGF 
VEGFsiRNA-PEI, 
PLGA microspheres 
Administered intratumourally [165] 
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Table 3.  A summary of clinical trials ongoing using siRNA including the delivery system, the route of administration, the disease target, the pharmaceutical 
company and the current status of the trial. 
 
siRNA Delivery System Route of Administration Disease Target 
Company/ 
Institution 
Status 
AGN211745 Naked siRNA Intavitreal Injection 
Wet Age-related Macular 
Degeneration 
VEGF receptor 
Allergan 
www.allergan.com 
Phase II 
(Halted) 
Bevasiranib Naked siRNA Intravitreal Injection 
Wet Age-related Macular 
Degeneration 
VEGF 
Opko Health Ltd 
www.opko.com 
Phase III 
(Terminated) 
PF-4523655 
(RTP801i-14) 
Modified siRNA Intravitreal Injection 
 
Diabetic Macular Edema; 
Wet Age-related Macular 
Degeneration 
 
Hypoxia-inducible 
gene 
Quark 
www.quarkpharma.com 
Phase II 
QPI-120 Modified siRNA Intravenous Injection Acute Kidney Injury  P53 
Quark 
www.quarkpharma.com 
Phase I/IIa 
QPI-120 Modified siRNA Intravenous Injection Delayed Graft Function P53 
Quark 
www.quarkpharma.com 
Phase I/II 
ALN-RSV01 Naked siRNA Intranasal 
Respiratory Syncytial 
Virus (RSV) 
RSV nucleocapsid 
Alnylam Pharmaceuticals 
www.alnylam.com 
Phase IIb 
TD101 Naked siRNA Injection into foot 
Pachyonychia congenital 
(PC) 
PC keratin K6a 
TransDerm 
www.transderminc.com 
Phase I 
CALAA-01 
 
Transferrin targeted 
cyclodextrin nanoparticles 
 
Intravenous Infusion Cancer RRM2 
Calando Pharmaceuticals 
www.calandopharma.com 
Phase I 
N/A 
Proteasome siRNA and 
tumour antigen RNA-
transfected dendritic cells 
Intradermal Injection Metastatic Melanoma 
Immunoproteasome 
beta subunits LMP2, 
LMP7 and MECL1 
Duke University 
www.cancer.duke.edu 
Phase I 
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Figure Legends 
 
Figure 1. Knockdown of endogenous mRNA using the RNAi pathway. 
(A) longer dsRNAs can be transfected into the cytoplasm, follow Dicer 
processing and are recognized by RISC, (B) synthetic siRNAs can be 
transfected into cells and loaded into RISC directly for the RNAi pathway, 
and (C) miRNA blocks translation with a less perfectly matched 
sequence. (Based on Ref 168) 
Figure 2. Systematic approach to the design, formulation and assessment 
of an “ideal” non-viral construct for cell specific targeted delivery of 
siRNA.  
 
Figure 3. Schematic of the proposed ABCD concept using cationic 
polymeric vectors as a model. A=siRNA, B=cationic polymer, C=PEG 
and D=targeting ligand.  
 
Figure 4. The structural concept of cyclodextrin:siRNA vesicles. 
Uncharged targeting (i.e. galactosylated) amphiphilic cyclodextrins can 
form a hydrophilic interior. This water interior acts as hosts to possibly 
encapsulate siRNA inside (Adapted from Ref 126). 
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